Press release
Gaucher's Disease Pipeline as Novel and Extensive 16+ Therapies Likely to Enter in the Treatment Domain
Key takeaways from the Gaucher's Disease Pipeline Report
• DelveInsight's Gaucher's Disease Pipeline report depicts a robust space with 14+ active players working to develop 16+ pipeline therapies for Gaucher's Disease.
• The leading Gaucher's Disease Companies such as Gain therapeutics, M6P Therapeutics, AvroBio, Orphazyme, Eli Lilly and Company, Sanofi, and others, are developing therapies for the Gaucher's disease treatment
• Gaucher's disease Emerging therapies such as - GBA programme, M 011, AVR-RD-02, Arimoclomol, GBA1 Gene Therapy, Venglustat, and others are expected to have a significant impact on the Gaucher's disease market in the coming years.
• The Gaucher's disease companies and academics are working to assess challenges and seek opportunities that could influence Gaucher's Disease R&D. The therapies under development are focused on novel approaches to treat/improve Gaucher's Disease.
Request a sample and discover the recent advances in Gaucher's Disease Treatment Drugs Report @ https://www.delveinsight.com/sample-request/gauchers-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Gaucher's Disease Overview
Gaucher disease (GD) is an inborn error of metabolism that affects the recycling of cellular glycolipids. It is an autosomal recessive inherited disorder of metabolism. The major clinical symptoms of GD include enlargement of the liver and spleen (hepatosplenomegaly), low number of red blood cells (anemia), easy bruising, and bone disease (bone pain and fractures). The diagnosis of GD is based on clinical symptoms and laboratory testing. A diagnosis of Gaucher disease is suspected in individuals who have bone problems, enlarged liver and spleen (hepatosplenomegaly), changes in red blood cell levels, easy bleeding and bruising from low platlets or signs of nervous system problems. Treatment is individualized for each patient depending on the type of Gaucher disease. Enzyme replacement therapy (ERT) has proven effective for individuals with Gaucher disease type 1.
Recent Developmental Activities in the Gaucher's Disease Treatment Landscape
• In April 2022, Sanofi initiated a parallel arm, Phase 3, double-blind,active-comparator, 2 arm study to evaluate the efficacy and safety of daily oral venglustat versus intravenous Cerezyme infusions every two weeks for improvement or stabilization of the neurological manifestations and maintenance of systemic disease stability in participants aged ≥12 and
• GPH301 is a next generation gene-edited autologous HSC product candidate leveraging the CCR5 locus technology for the treatment of Gaucher disease. With GPH301, a functional copy of the gene for glucocerebrosidase (GCase) is inserted into the chromosomal location of the CCR5 gene. The drug is in preclinical studies for the treatment of Gaucher's Disease.
• AVR-RD-02 is an ex vivo lentiviral gene therapy, designed using Avrobio's plato platform. The drug is in Phase I/II clinical studies for the treatment of Gaucher's Disease.
Gaucher's Disease Emerging Drugs Profile
• GPH301: Graphite Bio
• AVR-RD-02: AVROBIO
Gaucher's Disease Therapeutic Assessment
There are approx. 14+ key companies which are developing the therapies for Gaucher's Disease. The companies which have their Gaucher's Disease drug candidates in the most advanced stage, i.e. Phase I/II include, AVROBIO.
Get an overview of the Immune Thrombocytopenia Ongoing Clinical Trials Analysis @ https://www.delveinsight.com/report-store/gauchers-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Gaucher's disease Pipeline
• Coverage: Global
• Key Gaucher's disease Companies: Gain therapeutics, M6P Therapeutics, AvroBio, Orphazyme, Eli Lilly and Company, Sanofi, and others
• Key Gaucher's disease Therapies: GBA programme, M 011, AVR-RD-02, Arimoclomol, GBA1 Gene Therapy, Venglustat, and others
• Gaucher's disease Therapeutic Assessment: Gaucher's disease current marketed and Gaucher's disease emerging therapies
• Gaucher's disease Market Dynamics: Gaucher's disease market drivers and Gaucher's disease market barriers
Table of Content
1. Introduction
2. Executive Summary
3. Gaucher's Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Gaucher's Disease - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Eliglustat: Sanofi
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Arimoclomol: Orphazyme
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. AVR-RD-02: AVROBIO
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. CAN103: CANbridge Life Sciences
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Gaucher's Disease Key Companies
21. Gaucher's Disease Key Products
22. Gaucher's Disease- Unmet Needs
23. Gaucher's Disease- Market Drivers and Barriers
24. Gaucher's Disease- Future Perspectives and Conclusion
25. Gaucher's Disease Analyst Views
26. Appendix
Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Gaucher's Disease drugs?
• How many Gaucher's Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gaucher's Disease?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Gaucher's Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Gaucher's Disease and their status?
• What are the key designations that have been granted to the emerging drugs?
For further information on the Immune thrombocytopenia Pipeline therapeutics, reach out to Immune thrombocytopenia Treatment Landscape @ https://www.delveinsight.com/report-store/gauchers-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09193216187
Address: 304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Gaucher's Disease Pipeline as Novel and Extensive 16+ Therapies Likely to Enter in the Treatment Domain here
News-ID: 2844575 • Views: …
More Releases from DelveInsight Business Research
Alpha-1 Antitrypsin Deficiency Pipeline 2025: MOA and ROA Insights, Clinical Tri …
Alpha-1 Antitrypsin Deficiency pipeline constitutes 12+ key companies continuously working towards developing 12+ Alpha-1 Antitrypsin Deficiency treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Alpha-1 Antitrypsin Deficiency Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alpha-1 Antitrypsin Deficiency Market.
The Alpha-1 Antitrypsin Deficiency Pipeline report embraces in-depth commercial…
Alopecia Areata Market Expected to Gain Momentum Through 2034, According to Delv …
The Alopecia Areata market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Alopecia Areata pipeline products will significantly revolutionize the Alopecia Areata market dynamics.
DelveInsight's "Alopecia Areata Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Alopecia Areata, historical and forecasted epidemiology as well as the Alopecia Areata market trends in the United…
Acne Vulgaris Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Tria …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Acne Vulgaris pipeline constitutes 20+ key companies continuously working towards developing 22+ Acne Vulgaris treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Acne Vulgaris Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also…
Stargardt Disease Market Dynamics Indicate Upward Trajectory Through 2034, Repor …
The Stargardt Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Stargardt Disease pipeline products will significantly revolutionize the Stargardt Disease market dynamics.
DelveInsight's "Stargardt Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Stargardt Disease, historical and forecasted epidemiology as well as the Stargardt Disease market trends in the United…
More Releases for Gaucher
Gaucher & Pompe Diseases Enzyme Replacement Therapy (ERT) Market - Restoring Bal …
Newark, New Castle, USA: The "Gaucher & Pompe Diseases Enzyme Replacement Therapy (ERT) Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Gaucher & Pompe Diseases Enzyme Replacement…
Gaucher Disease Treatment Market Size | Share | Growth Analysis 2022
The global gaucher disease treatment market size was valued at USD 1,522.3 million in 2021 and is poised to grow at a significant CAGR of 1.2% during the forecast period 2022-28. Gaucher disease is a rare genetic disorder that affects the body's ability to break down a certain type of fat called glucocerebroside. This build-up of fat can cause a range of symptoms, including enlarged organs, bone pain, anemia, and…
Gaucher Disease Treatment Market Size | Share | Growth Analysis 2022
The global gaucher disease treatment market size was valued at USD 1,522.3 million in 2021 and is poised to grow at a significant CAGR of 1.2% during the forecast period 2022-28. Gaucher disease is a rare genetic disorder that affects the body's ability to break down a certain type of fat called glucocerebroside. This build-up of fat can cause a range of symptoms, including enlarged organs, bone pain, anemia, and…
Gaucher Disease Market Revenue Data Historic and Forecast Analysis
The market for Gaucher disease was estimated at USD 980.0 million in 2021, and it is anticipated to grow at a CAGR of 8.5% to reach around USD 1,800.0 million in 2029.
The rising prevalence of Gaucher disease, increasing awareness about Gaucher disease, and upsurge in the number of approved therapies for the treatment of Gaucher disease. Even it is the most prevalent lysosomal storage disorder, Gaucher disease is a rare…
Global Gaucher Disease Drugs Market Size – Forecast to 2026
The findings reviewed by GME stated that the Global Gaucher Disease Drugs Market will expand with a CAGR value of 2.1 percent from 2021 to 2026. The Gaucher disease treatment demand is primarily influenced by factors like the rising incidence of disease in both men and women of all ages and the resulting rise in the number of medications available in the marketplace. Also, a growing number of major players…
Gaucher Disease Market Size by 2025: QY Research
This recently published report examines the global Gaucher Disease market for the projected period of 7-years, i.e. between 2018 and 2025. The report highlights the accomplishments and opportunities lies in the market throughout the forecasted period. The report offers the thorough information about the overview and the scope of the global Gaucher Disease market along with its drivers, restraints, and trends. It also classifies the market into different segments such…
